Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734481 | 0.77 | — | — | |
| SCHEMBL2423612 | 0.72 | CDC7 (0.33) | CES1 | |
| SCHEMBL6657093 | 0.70 | — | — | |
| SCHEMBL3944498 | 0.68 | CES1 (0.35) | CES1PTPRC | |
| SCHEMBL14201295 | 0.64 | — | — | |
| SCHEMBL31116 | 0.63 | MEN1 (0.35) | CES1PTPRC | |
| Iodide SCHEMBL7508635 | 0.61 | S100A4 (0.34) | CES1PTPRC | |
| Fluoride SCHEMBL4741377 | 0.61 | MEN1 (0.33) | CES1PTPRC | |
| Hydrochloric Acid SCHEMBL3646726 | 0.61 | MEN1 (0.33) | CES1PTPRC | |
| Hydrochloric Acid SCHEMBL3397921 | 0.61 | MEN1 (0.33) | CES1PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-05-30 | — | — | US | disclosed |
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8273716-B2 | Use of LHRH antagonists for intermittent treatments | SPECTRUM PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-1644342-B1 | Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like | NEUROCRINE BIOSCIENCES INC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8148546-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8067456-B2 | Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs) | AETERNA ZENTARIS GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| EP-2278964-A1 | USE OF LHRH ANTAGONISTS AT NON-CASTRATING DOSES | Æterna Zentaris GmbH (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-1185530-A1 | IMIDAZO- AND PYRROLO[1,2-A]PYRIMID-4-ONES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | Neurocrine Biosciences, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6346534-B1 | IMIDAZOLO(1,2-A)- OR PYRROLO(1,2-A)-PYRIMIDONE DERIVATIVES; ANTICARCINOGENIC AGENTS; BENIGN PROSTATIC HYPERPLASIA; SEXUAL, GLANDULAR, SLEEP AND UROGENITAL DISORDERS; ENDOMETRIOSIS, IRRITABLE BOWEL SYNDROME | NEUROCRINE BIOSCIENCES, INC. | 2002-02-12 | — | — | US | disclosed |
| WO-2001055119-A2 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
| WO-2001029044-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000069859-A1 | IMIDAZO- AND PYRROLO[1,2-A]PYRIMID-4-ONES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-6015789-A | LUTEINIZING HORMONE RELEASING HORMONE AGONIST AND A LUTEINIZING HORMONE RELEASING HORMONE ANTAGONIST IN COMBINATION, | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-18 | — | — | US | disclosed |
| US-5977132-A | GALACTORRHEA, HYPERPROLACTINEMIC OVULATION, PROLACTINOMA AND BRAIN TUMORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0906115-A1 | COMBINED USE OF GnRH AGONIST AND ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997040846-A1 | COMBINED USE OF GnRH AGONIST AND ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
| EP-0781774-A2 | Prolactin production inhibitory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257395-A1 | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | CES1 3981/4885PTPRC 989/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | CES1 874/4885PTPRC 2117/4885 |
| US-11661430-B2 | Tetrazole derivatives as TRPA1 inhibitors | TRPA1, TRPV1, TRPV5 | CES1 3965/4885PTPRC 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.